ALS

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

Retrieved on: 
Wednesday, April 3, 2024
Athira Pharma, HGF, AAN, Nervous system, ALS, American Academy, Annual general meeting, American Academy of Neurology, Pharmaceutical industry

BOTHELL, Wash., April 03, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing novel small molecules to restore neuronal health and slow neurodegeneration, today announced a planned poster presentation at the upcoming American Academy of Neurology (AAN) 2024 Annual Meeting , to be held April 13 – 18, 2024, in Denver, Colorado and online.

Key Points: 
  • BOTHELL, Wash., April 03, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing novel small molecules to restore neuronal health and slow neurodegeneration, today announced a planned poster presentation at the upcoming American Academy of Neurology (AAN) 2024 Annual Meeting , to be held April 13 – 18, 2024, in Denver, Colorado and online.
  • The presentation will highlight preclinical data supporting the continued development of Athira's pipeline of small molecule candidates targeting the neurotrophic hepatocyte growth factor (HGF) system, including fosgonimeton for Alzheimer’s disease, ATH-1105 for amyotrophic lateral sclerosis (ALS), and ATH-1020 for Parkinson’s disease.
  • Athira’s drug development pipeline includes potential first-in-class (fosgonimeton) and next-generation (ATH-1105 and ATH-1020) small molecule drug candidates designed to promote the neurotrophic HGF system, which activates neuroprotective, neurotrophic and anti-inflammatory pathways in the nervous system.
  • Athira’s drug candidates have distinct properties, which the company believes may be applicable to a broad range of neurodegenerative diseases.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. (AMLX)

Retrieved on: 
Tuesday, April 2, 2024
ALS, Patient, GPM, Defendant, News, Suite, Investment, GAAP, Court, Pharmaceutical industry

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On November 9, 2023, Amylyx released its third quarter 2023 financial results, missing GAAP earnings per share consensus estimates by approximately 29%.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

Amylyx Pharmaceuticals, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; April 9, 2024 deadline

Retrieved on: 
Monday, April 1, 2024
Patient, Defendant, Apoptosis, ALS, Pharmaceutical industry

LOS ANGELES, April 01, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Amylyx Pharmaceuticals, Inc. investors that a lawsuit was filed on behalf of investors that purchased Amylyx securities between November 11, 2022 and November 8, 2023, inclusive (the “Class Period”).

Key Points: 
  • LOS ANGELES, April 01, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Amylyx Pharmaceuticals, Inc. investors that a lawsuit was filed on behalf of investors that purchased Amylyx securities between November 11, 2022 and November 8, 2023, inclusive (the “Class Period”).
  • Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 310-692-8883 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing.

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

Retrieved on: 
Monday, April 1, 2024
Research, PMN, FTLD, Biotechnology, MSA, ALS, Multiple system atrophy, CSF, Patient, Neuroscience, Epitope, Immunoglobulin G, RACK1, Cerebrospinal fluid, Activated, Synucleinopathy, Clinical trial, PROMIS, Antibody, Vaccination, Safety, Pharmacokinetics, Interim, Therapy, Blood, SAD, Frontotemporal lobar degeneration, Pharmaceutical industry

This is a very exciting opportunity for both ProMIS and the AD patients we aim to serve.

Key Points: 
  • This is a very exciting opportunity for both ProMIS and the AD patients we aim to serve.
  • ProMIS dosed the first participants in a first-in-human Phase 1a clinical trial of PMN310 as a potential treatment for AD in November 2023 (Study NCT06105528 ).
  • Using a proprietary computational platform, ProMIS identified potential conformational epitopes (misfolded portions) unique to toxic alpha-synuclein involved in synucleinopathies.
  • Cash and cash equivalents were $12.6 million as of December 31, 2023, compared to $5.9 million as of December 31, 2022.

Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information

Retrieved on: 
Tuesday, April 2, 2024
Amylyx Pharmaceuticals, Patient, Certification, Block & Leviton, ALS, Sodium phenylbutyrate/ursodoxicoltaurine

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) for securities law violations.

Key Points: 
  • BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) for securities law violations.
  • Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses.
  • Investors should contact Block & Leviton to learn more.
  • Block & Leviton is widely regarded as one of the leading securities class action firms in the country.

AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc.

Retrieved on: 
Monday, April 1, 2024
Apoptosis, ALS, District court, Patient, AMX0035, News, Prescription, Complaint, Action Replay, Amylyx Pharmaceuticals, Food, Court, Advertising, Pharmaceutical industry

If you purchased or acquired Amylyx securities, and/or would like to discuss your legal rights and options please visit Amylyx Pharmaceuticals, Inc.

Key Points: 
  • If you purchased or acquired Amylyx securities, and/or would like to discuss your legal rights and options please visit Amylyx Pharmaceuticals, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 9, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

Retrieved on: 
Monday, April 1, 2024
Employment, Brain, ALS, Patient, CNS, SVP, Cell biology, Bristol Myers Squibb, University, Initial, Myelocyte, Therapy, Drug development, Alkahest, Yale school, Clinical neuroscience, Compensated emancipation, Pharmaceutical industry

“I am pleased to welcome Jonas to Gain and look forward to his contributions.

Key Points: 
  • “I am pleased to welcome Jonas to Gain and look forward to his contributions.
  • His academic work focused on immuno-neurology, particularly on the effect of systemic inflammation on myeloid cells in the brain.
  • Previously, he served as Chief Medical Officer at Tranquis Therapeutics and Capacity Bio, SVP of Clinical Development at Alkahest, Medical Director at Denali Therapeutics, and Director of Neuroscience Discovery Medicine at UCB Pharma.
  • “Looking at the extensive data package that the Gain team has generated during preclinical development, Gain’s lead drug candidate GT-02287 has a first and best-in-class profile.

ROSEN, A LEADING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action – AMLX

Retrieved on: 
Sunday, March 31, 2024
Titan, Patient, Class, Amylyx Pharmaceuticals, Advertising, ALS, Court

WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMLX

Retrieved on: 
Sunday, March 31, 2024
Prior, Apoptosis, ALS, District court, Patient, AMX0035, Amyotrophy, Ext, LLP, Prescription, IBD, Complaint, Pomerantz, Action Replay, Food, Court, Evercore, Person, Pharmaceutical industry

NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.

Key Points: 
  • NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

AMLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Amylyx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Sunday, March 31, 2024
Apoptosis, ALS, Patient, AMX0035, Amyotrophy, Complaint, Court, Food, Person, Pharmaceutical industry

Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/AMLX .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/AMLX .
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.